Lanraplenib Completed Phase 2 Trials for Cutaneous Lupus Erythematosus (CLE) Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Completed | Treatment | 2 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT03134222 | Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) |